Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway

In conclusion, SFN ameliorates lipid metabolism disorders in NAFLD mice by upregulating FGF21/FGFR1 pathway. Our results verify that SFN may become a promising intervention to treat or relieve NAFLD.PMID:34654875 | DOI:10.1038/s41401-021-00786-2

Source: Acta Pharmacologica Sinica - October 16, 2021 Category: Drugs & Pharmacology Authors: Yi-Kuan Wu Zheng-Nan Ren Sheng-Long Zhu Yun-Zhou Wu Gang Wang Hao Zhang Wei Chen Zhao He Xian-Long Ye Qi-Xiao Zhai Source Type: research